New data show potential of Rasilez®* to protect kidneys from damage independent of its proven ability to lower blood pressure

04.06.08 - 23:51 ... source : Novartis

... AVOID study shows potential kidney protection benefits of Rasilez in type 2 diabetic patients with kidney disease and high blood pressure[1] Rasilez reduced albuminuria, a key indicator of kidney disease, by an additional 20% when added to maximum dose of angiotensin-receptor blocker losartan[1],[2] First clinical trial to present data on potential kidney-protective benefits of Rasilez, independent of its proven blood pressure reductions[3] Damage to kidneys caused by diabetes is leading cause of end-stage renal disease in developed countries[1] Basel, June 4, 2008 - Data published in this week's New England Journal of Medicine demonstrate that the first-in-class direct renin inhibitor Rasilez® (aliskiren), known as Tekturna® in the US, may have potential kidney-protective benefits that are independent of its already proven ability to provide powe ...» Next (HTML)